Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Mutation of Notch1 and Notch2 in human leukemia and/or lymphomaa

From: Current views on the role of Notch signaling and the pathogenesis of human leukemia

Leukemia and/or lymphoma type

Notch mutations in PEST/HD domain, %

Studies

Notch1

   T-ALL

50% PEST/HD

[16, 49]

   B-CLL

4.6% PEST

[50, 51]

   CLL

12.2% PEST

[52]

   AML

8.3% PEST

[53]

   T-NHL

42.9% PEST/HD

[49]

   ATL

30% PEST

[17]

Notch2

   DLBCL

8% PEST

[31]

   MZL

5% PEST

[32]

  1. aPEST: proline, glutamine, serine, and threonine; HD: heterodimerization domain; T-ALL: T-cell acute lymphoblastic leukemia; B-CLL: B-cell chronic lymphocytic leukemia; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia; T-NHL: T-cell non-Hodgkin lymphoma; ATL: adult T-cell leukemia; DLBCL: diffuse large B-cell lymphoma; MZL: marginal zone lymphoma.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us